Delgocitinib Ointment Dosing in Children
Author Information
Author(s): Fukuie Tatsuki, Toyama Hiroyuki, Tanaka Mai, Ohashi‐Doi Katsuyo, Kabashima Kenji
Primary Institution: National Center for Child Health and Development, TORII Pharmaceutical Co Ltd, Graduate School of Medicine Kyoto University
Hypothesis
What is the efficacy and safety of delgocitinib ointment in different concentrations for treating pediatric atopic dermatitis?
Conclusion
Delgocitinib 0.5% ointment may be more effective than the 0.25% dose for mild atopic dermatitis, and it is well tolerated when used in combination with topical corticosteroids and/or tacrolimus ointment.
Supporting Evidence
- 46.2% of subjects with mild disease achieved clear or almost clear skin with 0.25% delgocitinib.
- 71.4% of subjects with mild disease achieved clear or almost clear skin with 0.5% delgocitinib.
- 19.0% of subjects with moderate to severe disease achieved clear or almost clear skin with 0.25% delgocitinib.
- 20.0% of subjects with moderate to severe disease achieved clear or almost clear skin with 0.5% delgocitinib.
- No overall differences in safety profiles between the two doses were observed.
Takeaway
This study looked at a cream called delgocitinib for kids with skin problems. They found that a stronger version of the cream works better for mild cases and is safe to use with other medicines.
Methodology
Post-hoc analysis of data from two double-blind placebo-controlled trials comparing the efficacy and safety of 0.25% and 0.5% delgocitinib ointment in pediatric patients with atopic dermatitis.
Potential Biases
No data on the correlation between treatment-related adverse events and delgocitinib dose were collected.
Limitations
The study is based on post-hoc analyses of short-term treatment data from a relatively small number of patients.
Participant Demographics
Pediatric patients aged 2-15 years with atopic dermatitis.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website